Dexmedetomidine is, therefore, preferred over beta-blockers for heart rate control in patients with asthma and chronic obstructive pulmonary disease (COPD), where beta-blocker use may cause concomitant bronchoconstriction from beta-2 adrenergic receptor blockade. Here, ADRB2 is linked to chronic obstructive pulmonary disease.